TODD STRATEGY GROUP

Lobbying for BRISTOL-MYERS SQUIBB COMPANY · Biopharmaceutical company.

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Oct 20, 2025

Lobbying activity 2

Medicare/Medicaid

Biosimilars reimbursement issues. Supply Chain Issues. Pharmacy Benefit Manager Reform.

Health Issues

Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. 340B Program.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.